Ampersand Technologies

Ampersand Technologies is developing custom, precision genetic tests to enable evidence-based decision-making in horticulture, agriculture, biosecurity, and environmental monitoring. The technology has emerged as a challenger to PCR in the molecular diagnostics space and is already being used for point-of-need human medical diagnostics. Ampersand’s objective is to bring this technology to sectors that stand to benefit from using molecular diagnostics at the point-of-need, and to build a connected solution, providing a clear pathway to implementation for end users. Ampersand Technologies officially launched in August 2021. The start-up, which is being led by Dr. Richard Winkworth, received co-investment from Matū, a venture capital fund focused on early-stage science and technology, and Massey Ventures, the company responsible for commercialising innovative research at Massey University.